ZOLGENSMA® (onasemnogene abeparvovec-xioi)

Intended for US audiences only.

Please read the Full Prescribing Information, including Boxed Warning, at https://bit.ly/zolgensma-pi. Please read and listen to the Indication and Important Safety Information on the home tab of this channel.

A diagnosis of spinal muscular atrophy (SMA) can have a big impact on families, as can treatment with ZOLGENSMA® (onasemnogene abeparvovec-xioi). Take a moment and watch these inspirational videos of families living with SMA as they share what the day of treatment with ZOLGENSMA means to them and how their child is doing after treatment.

Results and outcomes vary among children based on several factors, including how far their SMA symptoms progressed prior to receiving treatment.

You’ll also find educational videos and resources available to your family that can help you learn more about ZOLGENSMA.

© 2023 Novartis Gene Therapies, Inc. 
Bannockburn, IL 60015 
10/2023 US-ZOL-20-0523 V6